GlassScriptPhysician profile
Brian L Donner
NPI 1972544492
$1,119.31
in general payments reported to CMS, 2019-2025
16 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $124 · 2021: $184 · 2022: $290 · 2023: $110 · 2024: $20.85 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314 · Education: $26.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.06 |
| Education | $26.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $227.43 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $196.24 | 2019-2022 | |
| Amgen INC. | $131.96 | 2019-2025 | Tavneos |
| Baxter Healthcare | $78.63 | 2021-2023 | Renal - Extraneal Solution |
| Mallinckrodt Hospital Products INC. | $74.38 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.51 | 2025 | Jardiance |
| Vifor Pharma, INC. | $52.87 | 2019-2022 | |
| Horizon Therapeutics Plc | $51.84 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $43.87 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $38.36 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $36.80 | 2021-2022 | |
| Travere Therapeutics, INC. | $35.15 | 2023-2025 | |
| Akebia Therapeutics INC | $32.34 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $18.72 | 2025 | Ultomiris |
| Glaxosmithkline, LLC. | $17.84 | 2023 | Benlysta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $16.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Donner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.